NOVANTA INC. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; unaudited. Comparisons are with the three and six months ended July 1, 2022. Amounts below are in U.S. dollars unless stated otherwise.
Business context and results
Novanta supplies precision technology and components to medical and advanced industrial OEMs. Its three reporting segments are Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. Segment names changed in 2023, without changing segment composition or historical results.
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $229.5m | $215.4m | $448.6m | $419.6m |
| Gross profit | $104.1m | $95.2m | $201.8m | $185.5m |
| Gross margin | 45.4% | 44.2% | 45.0% | 44.2% |
| Operating income | $32.2m | $23.3m | $58.5m | $47.6m |
| Net income | $20.9m | $17.5m | $39.1m | $36.3m |
| Diluted EPS | $0.58 | $0.49 | $1.09 | $1.01 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $36.4m | $35.4m |
Financial position and cash flow
- Cash and equivalents were $91.3m at June 30, down from $100.1m at year-end 2022. Six-month cash declined $8.8m.
- Debt under senior credit facilities totaled $408.5m, down from $435.5m at December 31, 2022. Net debt, using reported cash, was approximately $317.2m.
- Unused and available revolving credit capacity was $363.4m. The facility maturity is March 2027; the company reported compliance with its covenants. Leverage ratio was 2.00 against a maximum of 3.50, and fixed-charge coverage was 5.63 against a minimum of 1.50.
- Six-month investing cash outflow was $6.9m, all capital expenditures. Financing cash outflow was $40.8m, primarily debt repayments of $30.5m and payroll taxes on vested share awards of $10.0m.
- Cash interest paid was $12.7m for the first six months, versus $5.2m a year earlier. The weighted-average facility interest rate was 5.84% for the six-month period, compared with 2.39%.
- Current assets were $414.3m and current liabilities $136.0m. Operating lease liabilities totaled $48.6m.
Material changes and segment performance
- Q2 revenue rose 6.6%; first-half revenue rose 6.9%. Management attributed growth mainly to demand in medical and advanced industrial markets and prior-year acquisition contributions. Acquisition revenue contributed $3.3m in Q2 and $6.8m for the first half.
- Medical Solutions revenue increased 27.2% in Q2 and 26.2% for the first half, reflecting medical demand and acquisition contributions. Precision Medicine and Manufacturing grew 7.0% and 8.8%, respectively.
- Robotics and Automation revenue fell 10.7% in Q2 and 10.0% for the first half, primarily due to weaker microelectronics demand. Its first-half gross margin declined to 47.1% from 48.2%.
- Q2 operating income increased 38.2%; first-half operating income increased 23.0%. Higher gross profit and lower purchased-intangible amortization supported results; first-half restructuring charges and higher R&D and SG&A partly offset the gains.
- First-half revenue by end market was approximately 53% medical and 47% advanced industrial, compared with 47% and 53%, respectively, a year earlier. U.S. revenue grew notably, while China revenue declined year over year in both the quarter and first half.
Outlook, commentary, and risks
- Management expects operating cash flows to cover operating and capital expenditure needs for at least the next 12 months. It expects 2023 capital expenditures of approximately $25m–$30m, including a significant U.K. facility buildout.
- The 2022 restructuring program is expected to be substantially complete by year-end 2023, with a further $1.5m–$2.0m of charges expected. The 2020 program is also expected to finish in 2023, with another $0.5m–$1.0m of charges expected.
- The filing provides no specific full-year revenue or EPS guidance. Management said customer backlog coverage remained comparable to year-end 2022 and anticipated customers would gradually shorten order lead times as supply disruptions ease.
- Risks highlighted include persistent inflation in materials, components, and labor; higher interest rates; supply-chain and transportation disruption; demand variability and cyclicality in advanced industrial markets, particularly microelectronics; OEM customer order timing; foreign exchange, regulatory, and geopolitical risks. Price increases and productivity actions may not fully offset cost inflation.
- The company reported ordinary-course legal claims and does not expect their outcomes to materially affect its financial statements, while noting that no assurance is possible. No material changes to purchase commitments were reported. The annual goodwill and indefinite-lived intangible impairment test found no impairment.
Important facts for investors to verify
- Whether microelectronics weakness and shorter customer lead times affect Robotics and Automation revenue, backlog, and factory utilization.
- Whether medical segment growth and gross-margin improvement persist, and how much growth reflects acquisition contributions.
- How rising interest expense affects earnings and debt reduction, and whether cash generation supports planned capital spending.
- Whether restructuring programs deliver expected cost and margin benefits, including the remaining charges and completion timing.
- Whether inflation, supply constraints, or demand weakness prevent full cost recovery or change management’s liquidity outlook.